CD7-directed CAR T-cell therapy: a potential immunotherapy strategy for relapsed/refractory acute myeloid leukemia

CD7-directed CAR T-cell therapy: a potential immunotherapy strategy for relapsed/refractory acute myeloid leukemia

Abstract Relapsed/refractory acute myeloid leukemia (AML) patients generally have a dismal prognosis and the treatment remains challenging. Due to the expression of CD7 on 30% AML and not on normal myeloid and erythroid cells, CD7 is an attractive target for immunotherapy of AML. CD7-targeted CAR T-...

Full description

Bibliographic Details
Main Authors: Xuanqi Cao, Haiping Dai, Qingya Cui, Zheng Li, Wenhong Shen, Jinlan Pan, Hongjie Shen, Qinfen Ma, Mengyun Li, Sifan Chen, Juncheng Chen, Xiaming Zhu, Huimin Meng, Lin Yang, Depei Wu, Xiaowen Tang
Format: Article
Language:English
Published: BMC 2022-09-01
Series:Experimental Hematology & Oncology
Subjects:
Chimeric antigen receptor T‑cells
CD7
Acute myeloid leukemia
Relapsed/refractory
Online Access:https://doi.org/10.1186/s40164-022-00318-6

Internet

https://doi.org/10.1186/s40164-022-00318-6

Similar Items